CA-15-3 BioAssay(TM) ELISA Kit

Breast cancer is the most common life-threatening malignant lesion in women of many developed countries today, with approximately 180,000 new cases diagnosed every year. Roughly half of these newly diagnosed patients are node-negative, however 30% of these cases progress to metastatic disease. There are a number of tumor markers that can help clinicians to identify and diagnose which breast cancer patients will have aggressive disease and which will have an indolent course. These markers include estrogen and progesterone receptors, DNA ploidy and percent-S phase profile, epidermal growth factor receptor, HER-2/neu oncogene, p53 tumor suppressor gene, cathepsin D, proliferation markers and CA15-3. CA15-3 is most useful for monitoring patients post-operatively for recurrence, particularly metastatic diseases. 96% of patients with local and systemic recurrence have elevated CA15-3, which can be used to predict recurrence earlier than radiological and clinical criteria. A 25% increase in the serum CA15-3 is associated with progression of carcinoma. A 50% decrease in serum CA15-3 is associated with response to treatment. CA15-3 are more sensitive than CEA in early detection of breast cancer recurrence. In combination with CA-125, CA15-3 has been shown to be useful in early detection of relapse of ovarian cancer. CA15-3 levels are also increased in colon, lung and hepatic tumors. Detection Range: 0-200U/ml Specificity: 97% Sensitivity: 5units/ml Kit Components: Microtiter Plate, 1x96wells Sample DIluent, 1x100ml Enzyme Conjugate Reagent, 1x22ml Standard 0unit/ml, 1x1vial Standard 15unit/ml, 1x1vial Standard 30unit/ml, 1x1vial Standard 60unit/ml, 1x1vial Standard 120unit/ml, 1x1vial Standard 240unit/ml, 1x1vial TMB Substrate, 1x12ml Stop Solution, 1x12ml Wash Buffer Concentrate (50X), 1x15ml Storage and Stability: Store all components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.